Skip to content

Ayurvedic management of coronary artery diseases

EVALUATING CLINICAL EFFICACY OF VIRECHAN AND RASAYAN THERAPY (GO-MUTRA HARITAKI) IN THE MANAGEMENT OF HRUDROGA (CORONARY ARTERY DISEASES)- A RANDOMIZED CONTROL CLINICAL TRIAL

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/12/038569
Enrollment
70
Registered
2021-12-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I20-I25- Ischemic heart diseases

Interventions

None listed

Sponsors

All India Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Both sex 2. Age group between 20-70 years 3. Class I, II&IIa (III) as per Canadian Cardiovascular Society grading of angina pectoris 4.CAC Scoring 5. ECG- T wave inverted without Q wave / ST elevation 6.Stress TMT- Positive 7. Angiography- 8. Those are able to give written consent

Exclusion criteria

Exclusion criteria: 1.Renal insufficiency (S. Creatinine > 2 mg/dl, Blood Urea > 40 mg/dl) 2.â?•2D ECHO showing the presence of any valvular heart disease 3.Tachycardia( >160/min)/ Ventricular arrhythmia 4. Low Left Ventricular Ejection Fraction (LVEF 4.â?•Positive Troponin Test 5.CT Angiography lesion > 60% 6.â?•CPK-MB > 5% 7. Prolonged or traumatic cardiovascular resuscitation 8. Previous Coronary Intervention (within 3 months) or any bypass surgery 9. Ischemic Cerebral stroke within past one months 10. Peripheral arterial diseases 11. Recent Head trauma or known intracranial neoplasm 12. Suspected aortic dissection 13. Prolonged chest pain ( > 30mints) associated with vomiting and syncope 14. Chest pain with vagotonia (bradycardia, pallor, and syncope) 15. Haemorrhagic stroke within past one month 16. Diabetic haemorrhagic retinopathy or other haemorrhagicopthalamic conditions. 17. Recorded uncontrolled Blood Pressure >180/100mmHg in three consecutive readings 18. Active peptic ulcer 19. Significant liver dysfunction 20.â?•Raised Prothrombin time, Activated Partial Thromboplastin Time 21.â?•Heart failure (Brain Natriuretic Peptide > 2 times) 22. Active bleeding, Known bleeding diathesis or current use of anticoagulant 23. BMI 24. All VirechanAnarha patients as mentioned in Ch. Si 2/11 will be excluded VirechanAnarha are Subhag, Kshatgud, Muktanal, Adhog Raktapitta, Vilanghit,Durbal, Alpagni, Adivya nirudhaka, Ajirna, Nawajwar, Madatyay, Aadhman, Shalyadrit, Atisnigdha, Atiruksha, Krurkoshtha, Urahkshat, Kshina, Atisthul, Atikrusha, Garbhini. Any other case if investigator feels could not include in the study during the course of study (â?• Investigation will be done if feasible)

Design outcomes

Primary

MeasureTime frame
Change in Cardiac computed tomography angiography (CCTA)Timepoint: 3 months

Secondary

MeasureTime frame
Change in followings- 1.Change in coronary artery calcium scoring. 2.Change in stress TMT. 3.Change in Chest Pain/ Discomfort Questionnaires, 4.SF-36 5.BODE Index. Timepoint: 3 months

Countries

India

Contacts

Public ContactDr Divya Kajaria

All India Institute Of Ayurveda, New Delhi

Divyakajaria@gmail.com8826167515

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026